Risk of developing pneumonia is enhanced by the combined traits of fluoroquinolone resistance and type III secretion virulence in respiratory isolates of pseudomonas aeruginosa

Critical Care Medicine

Volumn 42, Issue 1, 2014, Pages 48-56

  Sullivan, Eva ^a,b   Bensman, Joyce ^b   Lou, Mimi ^b   Agnello, Melissa ^b   Shriner, Kimberly ^a   Wong Beringer, Annie ^a,b  

^a HUNTINGTON MEMORIAL HOSPITAL   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

bronchitis; colonization; fluoroquinolone resistance; pneumonia; Pseudomonas aeruginosa; type III secretion system

Indexed keywords

AMIKACIN; AZTREONAM; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN;

AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; APACHE; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL COLONIZATION; BACTERIAL GENE; BACTERIAL VIRULENCE; BRONCHITIS; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; ENTERIC FEEDING; EXOS GENE; EXOU GENE; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; PCRV GENE; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; RISK FACTOR; TYPE III SECRETION SYSTEM; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 84891504003     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e318298a86f     Document Type: Article

References (40)

1. Rello J, Díaz E, Rodríguez A: Etiology of ventilator-associated pneumonia. Clin Chest Med 2005; 26:87-95
2. Gaynes R, Edwards JR; National Nosocomial Infections Surveillance System: Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 2005; 41:848-854
3. Hauser AR, Cobb E, Bodi M, et al: Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit Care Med 2002; 30:521-528
4. Hauser AR: The type III secretion system of Pseudomonas aeruginosa: Infection by injection. Nat Rev Microbiol 2009; 7:654-665
5. Feltman H, Schulert G, Khan S, et al: Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa. Microbiology 2001; 147(Part 10):2659-2669
6. Allewelt M, Coleman FT, Grout M, et al: Acquisition of expression of the Pseudomonas aeruginosa ExoU cytotoxin leads to increased bacterial virulence in a murine model of acute pneumonia and systemic spread. Infect Immun 2000; 68:3998-4004
7. Shaver CM, Hauser AR: Relative contributions of Pseudomonas aeruginosa ExoU, ExoS, and ExoT to virulence in the lung. Infect Immun 2004; 72:6969-6977
8. Diaz MH, Hauser AR: Pseudomonas aeruginosa cytotoxin ExoU is injected into phagocytic cells during acute pneumonia. Infect Immun 2010; 78:1447-1456
9. Roy-Burman A, Savel RH, Racine S, et al: Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J Infect Dis 2001; 183:1767-1774
10. Neuhauser MM, Weinstein RA, Rydman R, et al: Antibiotic resistance among gram-negative bacilli in US intensive care units: Implications for fluoroquinolone use. JAMA 2003; 289:885-888
11. Kriengkauykiat J, Porter E, Lomovskaya O, et al: Use of an efflux pump inhibitor to determine the prevalence of efflux pump-mediated fluoroquinolone resistance and multidrug resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005; 49:565-570
12. Hsu DI, Okamoto MP, Murthy R, et al: Fluoroquinolone-resistant Pseudomonas aeruginosa: Risk factors for acquisition and impact on outcomes. J Antimicrob Chemother 2005; 55:535-541
13. Wong-Beringer A, Wiener-Kronish J, Lynch S, et al: Comparison of type III secretion system virulence among fluoroquinolone-susceptible and-resistant clinical isolates of Pseudomonas aeruginosa. Clin Microbiol Infect 2008; 14:330-336
14. Agnello M, Wong-Beringer A: Differentiation in quinolone resistance by virulence genotype in Pseudomonas aeruginosa. PLoS One 2012; 7:e42973
15. Sadikot RT, Blackwell TS, Christman JW, et al: Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med 2005; 171:1209-1223
16. Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing: Twentieth Informational Supplement M100-S20. Wayne, PA, CLSI Wayne, 2010
17. Magiorakos AP, Srinivasan A, Carey RB, et al: Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18:268-281
18. Ajayi T, Allmond LR, Sawa T, et al: Single-nucleotide-polymorphism mapping of the Pseudomonas aeruginosa type III secretion toxins for development of a diagnostic multiplex PCR system. J Clin Microbiol 2003; 41:3526-3531
19. Mahenthiralingam E, Campbell ME, Foster J, et al: Random amplified polymorphic DNA typing of Pseudomonas aeruginosa isolates recovered from patients with cystic fibrosis. J Clin Microbiol 1996; 34:1129-1135
20. Horan TC, Andrus M, Dudeck MA: CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36:309-332
21. Craven DE, Hudcova J, Lei Y: Diagnosis of ventilator-associated respiratory infections (VARI): Microbiologic clues for tracheobronchitis (VAT) and pneumonia (VAP). Clin Chest Med 2011; 32:547-557
22. American Thoracic Society, Infectious Diseases Society of America: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416
23. Bonten MJ, Bergmans DC, Ambergen AW, et al: Risk factors for pneumonia, and colonization of respiratory tract and stomach in mechanically ventilated ICU patients. Am J Respir Crit Care Med 1996; 154:1339-1346
24. von Baum H, Welte T, Marre R, et al; CAPNETZ Study Group: Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: Diagnosis, incidence and predictors. Eur Respir J 2010; 35:598-605
25. Yang K, Zhuo H, Guglielmo BJ, et al: Multidrug-resistant Pseudomonas aeruginosa ventilator-associated pneumonia: The role of endotracheal aspirate surveillance cultures. Ann Pharmacother 2009; 43:28-35
26. El Solh AA, Akinnusi ME, Wiener-Kronish JP, et al: Persistent infection with Pseudomonas aeruginosa in ventilator-associated pneumonia. Am J Respir Crit Care Med 2008; 178:513-519
27. Saliba AM, Nascimento DO, Silva MC, et al: Eicosanoid-mediated proinflammatory activity of Pseudomonas aeruginosa ExoU. Cell Microbiol 2005; 7:1811-1822
28. Henderson FC, Miakotina OL, Mallampalli RK: Proapoptotic effects of P. aeruginosa involve inhibition of surfactant phosphatidylcholine synthesis. J Lipid Res 2006; 47:2314-2324
29. Sutterwala FS, Mijares LA, Li L, et al: Immune recognition of Pseudomonas aeruginosa mediated by the IPAF/NLRC4 inflammasome. J Exp Med 2007; 204:3235-3245
30. Dorman CJ, Corcoran CP: Bacterial DNA topology and infectious disease. Nucleic Acids Res 2009; 37:672-678
31. Galán JE, Curtiss R 3rd: Expression of Salmonella typhimurium genes required for invasion is regulated by changes in DNA supercoiling. Infect Immun 1990; 58:1879-1885
32. Singh G, Wu B, Baek MS, et al: Secretion of Pseudomonas aeruginosa type III cytotoxins is dependent on pseudomonas quinolone signal concentration. Microb Pathog 2010; 49:196-203
33. Li L, Ledizet M, Kar K, et al: An indirect enzyme-linked immunosorbent assay for rapid and quantitative assessment of Type III virulence phenotypes of Pseudomonas aeruginosa isolates. Ann Clin Microbiol Antimicrob 2005; 4:22
34. Marshall RP, Gohlke P, Chambers RC, et al: Angiotensin II and the fibroproliferative response to acute lung injury. Am J Physiol Lung Cell Mol Physiol 2004; 286:L156-L164
35. Sawa T, Yahr TL, Ohara M, et al: Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury. Nat Med 1999; 5:392-398
36. Neely AN, Holder IA, Wiener-Kronish JP, et al: Passive anti-PcrV treatment protects burned mice against Pseudomonas aeruginosa challenge. Burns 2005; 31:153-158
37. François B, Luyt CE, Dugard A, et al: Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: A randomized, double-blind, placebo-controlled trial. Crit Care Med 2012; 40:2320-2326
38. Lee VT, Pukatzki S, Sato H, et al: Pseudolipasin A is a specific inhibitor for phospholipase A2 activity of Pseudomonas aeruginosa cytotoxin ExoU. Infect Immun 2007; 75:1089-1098
39. Arnoldo A, Curak J, Kittanakom S, et al: Identification of small molecule inhibitors of Pseudomonas aeruginosa exoenzyme S using a yeast phenotypic screen. PLoS Genet 2008; 4:e1000005
40. Draper M, Garrity-Ryan LK, Donovan P, et al: A novel anti-virulence approach for treatment of Pneumonia caused by Pseudomonas aeruginosa. 47th ASM Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 2007, Abstract F2-968a